About SynDevRx
Board of Directors
Richard L. Love
Director; Managing Partner, Translational Accelerator LLC
Richard L. Love has 40 years of industry experience, with more than 27 years of leadership roles in the biosciences industry. He started two biopharmaceutical companies, Triton Biosciences Inc. (Alameda, CA) and ILEX Oncology Inc. (ILXO, San Antonio, TX) and served as CEO in both companies for periods of eight years each. In addition Richard has served in senior executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center in San Antonio, and the Translational Genomics Research Institute (TGen) in Phoenix.
At Triton and ILEX, Richard led teams that were responsible for the clinical development of four approved therapies: Betaseron® for multiple sclerosis, Fludara® and CAMPATH® both for chronic lymphocytic leukemia, and Clolar® for acute leukemias.
In 2004 ILEX was acquired by Genzyme Corporation for approximately $1B. Currently Richard is a managing partner in Translational Accelerator LLC, an Arizona-based venture capital investment firm, and also serves on the Boards of PAREXEL International (PRXL), ImaRx Therapeutics (IMRX), MedTrust, LLC, and Cell Therapeutics.
Eric Tooker, J.D.
President, CEO Medical Consultant Services, Managing Partner Translational Accelerator LLC
Mr. Tooker is a Manager of Translational Accelerator, LLC, a $20M biotech venture fund in Phoenix, Arizona. He is also President and CEO of MCS Biotech Resources, which provides business, legal, administrative, and support services to expert medical consultants and start up companies. Mr. Tooker previously served as Vice President and General Counsel for Central Newspapers, Inc., until the company was acquired by Gannett Co., Inc. He has extensive experience in advising executive business teams throughout his 20 years as in-house counsel. In that role with Conseco, Inc., he served as legal counsel and business adviser for a significant private equity portfolio and led mergers and acquisitions and associated bank financings. Mr. Tooker earned a B.S. degree in education from Miami University-Ohio and a J.D. from the University of Michigan Law School.
Bradley Carver
Co-Founder, President, CEO SynDevRx, Inc.
Mr. Carver has over 16 years experience as a biotech senior executive. He previously served at President, CEO and Chairman of the Board of GlycoGenesys (Russell 2000 and NASDAQ listed). He successfully completed partnership deals with top tier pharmaceutical companies, and developed and put into clinical trials one of the world's first complex carbohydrate cancer drug candidates. Mr. Carver's led the company to solve extremely complex manufacturing and characterization issues, identify and characterize multiple mechanisms of action for their platform carbohydrate technology. He led the clinical trial program design effort and was key in selecting the target indications. Mr. Carver attended Michigan State University, where he received his BA in Business.
James Shanahan
Co-Founder, VP Business Development, SynDevRx, Inc.
Mr. Shanahan was founder and VP Marketing of his most recent company - JAM Technologies, Inc., where he successfully licensed the company's novel technology to AKM Japan, and was instrumental in forming a strategic co-development partnership with Intel. Jim also built the company's sales and distribution channels in Asia, plus established the company's market positioning with industry leaders including Bose, Apple Computer, Dell, National Semiconductor, and SRS among others. He also was responsible for establishing sales opportunities with major OEMs in Japan, Taiwan, China and Korea. Mr. Shanahan was in charge of operations at JAM including financing, legal, licensing, IP, and strategic planning, and has one issued semiconductor patent. Mr Shanahan attended the University of Massachusetts at Amherst where he studied engineering and language, and L'Universite Catholique, Angers France, where he studied language and history.
